AAAAAA

   
Results: 1-17 |
Results: 17
PERFORMANCE EVALUATION OF THE AGII CHEMISTRY ANALYZER
Authors: CRAMB R GARVEY K WALL DA BAKER R
Citation: R. Cramb et al., PERFORMANCE EVALUATION OF THE AGII CHEMISTRY ANALYZER, Clinical chemistry, 44, 1998, pp. 259-259
ADVERSE CHANGE IN LOW-DENSITY-LIPOPROTEIN SUBFRACTIONS PROFILE WITH ESTROGEN-ONLY HORMONE REPLACEMENT THERAPY
Authors: RAJMAN I LIP GYH CRAMB R MAXWELL SRJ ZARIFIS J BEEVERS DG KENDALL MJ
Citation: I. Rajman et al., ADVERSE CHANGE IN LOW-DENSITY-LIPOPROTEIN SUBFRACTIONS PROFILE WITH ESTROGEN-ONLY HORMONE REPLACEMENT THERAPY, Quarterly Journal of Medicine, 89(10), 1996, pp. 771-778
INVESTIGATION OF LOW-DENSITY-LIPOPROTEIN SUBFRACTIONS AS A CORONARY RISK FACTOR IN NORMOTRIGLYCERIDAEMIC MEN
Authors: RAJMAN I KENDALL MJ CRAMB R HOLDER RL SALIH M GAMMAGE MD
Citation: I. Rajman et al., INVESTIGATION OF LOW-DENSITY-LIPOPROTEIN SUBFRACTIONS AS A CORONARY RISK FACTOR IN NORMOTRIGLYCERIDAEMIC MEN, Atherosclerosis, 125(2), 1996, pp. 231-242
CONTROVERSIES IN HYPERLIPIDEMIA - ISSUES RESOLVED
Authors: CRAMB R
Citation: R. Cramb, CONTROVERSIES IN HYPERLIPIDEMIA - ISSUES RESOLVED, British Journal of Hospital Medicine, 56(11), 1996, pp. 566-567
PARTICLE-SIZE - THE KEY TO THE ATHEROGENIC LIPOPROTEIN
Authors: RAJMAN I MAXWELL S CRAMB R KENDALL M
Citation: I. Rajman et al., PARTICLE-SIZE - THE KEY TO THE ATHEROGENIC LIPOPROTEIN, Quarterly Journal of Medicine, 87(12), 1994, pp. 709-720
BRITISH FAMILY HEART-STUDY - ITS DESIGN AND METHOD, AND PREVALENCE OFCARDIOVASCULAR RISK-FACTORS
Authors: WOOD DA KINMONTH AL DAVIES G YARWOOD J THOMPSON SG PYKE SDM KOK Y CRAMB R LEGUEN C COLES C DURRINGTON P MARTEAU T ODWYER A STEELE DW BICKNELL C
Citation: Da. Wood et al., BRITISH FAMILY HEART-STUDY - ITS DESIGN AND METHOD, AND PREVALENCE OFCARDIOVASCULAR RISK-FACTORS, British journal of general practice, 44(379), 1994, pp. 62-67
EFFECT OF NONATTENDERS ON THE POTENTIAL OF A PRIMARY-CARE PROGRAM TO REDUCE CARDIOVASCULAR RISK IN THE POPULATION
Authors: DAVIES G PYKE S KINMONTH AL WOOD DA COLES C CRAMB R DURRINGTON P KOK Y LEGUEN C MARTEAU T ODWYER A PYKE SMD STEELE DW THOMPSON SG YARWOOD J
Citation: G. Davies et al., EFFECT OF NONATTENDERS ON THE POTENTIAL OF A PRIMARY-CARE PROGRAM TO REDUCE CARDIOVASCULAR RISK IN THE POPULATION, BMJ. British medical journal, 309(6968), 1994, pp. 1553-1556
RANDOMIZED CONTROLLED TRIAL EVALUATING CARDIOVASCULAR SCREENING AND INTERVENTION IN GENERAL-PRACTICE - PRINCIPAL RESULTS OF BRITISH FAMILY HEART-STUDY
Authors: WOOD DA KINMONTH AL DAVIES GA YARWOOD J THOMPSON SG PYKE SDM KOK Y CRAMB R LEGUEN C MARTEAU TM DURRINGTON PN
Citation: Da. Wood et al., RANDOMIZED CONTROLLED TRIAL EVALUATING CARDIOVASCULAR SCREENING AND INTERVENTION IN GENERAL-PRACTICE - PRINCIPAL RESULTS OF BRITISH FAMILY HEART-STUDY, BMJ. British medical journal, 308(6924), 1994, pp. 313-320
PULMONARY-HYPERTENSION AND PREGNANCY - A SERIES OF 8 CASES
Authors: SMEDSTAD KG CRAMB R MORISON DH
Citation: Kg. Smedstad et al., PULMONARY-HYPERTENSION AND PREGNANCY - A SERIES OF 8 CASES, Canadian journal of anaesthesia, 41(6), 1994, pp. 502-512
THE OXIDATION HYPOTHESIS OF ATHEROSCLEROSIS
Authors: RAJMAN I KENDALL M CRAMB R
Citation: I. Rajman et al., THE OXIDATION HYPOTHESIS OF ATHEROSCLEROSIS, Lancet, 344(8933), 1994, pp. 1363-1364
POSTOPERATIVE GLUCOSE-METABOLISM IN LIVER-TRANSPLANT RECIPIENTS - A 2-YEAR PROSPECTIVE RANDOMIZED STUDY OF CYCLOSPORINE VERSUS FK506
Authors: KRENTZ AJ DMITREWSKI J MAYER D MCMASTER P BUCKELS J DOUSSET B CRAMB R SMITH JM NATTRASS M
Citation: Aj. Krentz et al., POSTOPERATIVE GLUCOSE-METABOLISM IN LIVER-TRANSPLANT RECIPIENTS - A 2-YEAR PROSPECTIVE RANDOMIZED STUDY OF CYCLOSPORINE VERSUS FK506, Transplantation, 57(11), 1994, pp. 1666-1669
SERUM-LIPIDS AND APOLIPOPROTEINS IN LIVER-TRANSPLANT RECIPIENTS - A COMPARATIVE-STUDY OF CYCLOSPORINE-A AND FK-506
Authors: KRENTZ AJ CRAMB R DOUSSET B MAYER D MCMASTER P BUCKELS J SMITH JM NATTRASS M
Citation: Aj. Krentz et al., SERUM-LIPIDS AND APOLIPOPROTEINS IN LIVER-TRANSPLANT RECIPIENTS - A COMPARATIVE-STUDY OF CYCLOSPORINE-A AND FK-506, The Journal of laboratory and clinical medicine, 124(3), 1994, pp. 381-385
A ONE-YEAR MULTICENTER STUDY OF SIMVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA
Authors: GRAHAM I ROBINSON K TOMKIN G BRADFORD NC WILKINSON P BUCKLEY B SEED M MARENAH CB SILAS J CAPLICE N FENNELL W",KALEEM,"WENT J REPPER J VANNAN M TAYLOR D RICHARDSON PJ",RITTOO,"GRANT A COUNIHAN TB HERSH AD GUPTHA S GENTRY R YOUNG J GWILT DJ FOX K MULCAHY D GREENWOOD RH ROWLANDS DB CRAMB R",ARNSTEN,"MOURANT AJ",ROBERTS,SANTRY,"TAYLOR WH WALKER BA ALLEN S WOOD DA IVERSEN SA LAKER MF GAMA RM HUGHES EA POLANSKA A BENNETT ED",FARRELL,"WRAY R GINKS S CREAN PA HALL M HARTLEY P OCONNOR P WALSH M BAYNES C ELKELES RS BLOOMFIELD P WRIGHT R LINDSEY J CULLEN P MI MA FEELY J LOCKTON A",COLLINSON,"FINK RS WILSON I MILLER JP DAVIES R PATTERSON DLH BRUCE R CROOK D WYNN V OLIVER M
Citation: I. Graham et al., A ONE-YEAR MULTICENTER STUDY OF SIMVASTATIN IN THE TREATMENT OF HYPERCHOLESTEROLEMIA, British journal of clinical practice, 48(5), 1994, pp. 231-235
CLINICAL-EVALUATION OF SODIUM-ION SELECTIVE FIELD-EFFECT TRANSISTORS FOR WHOLE-BLOOD ASSAY
Authors: THOMPSON JM SMITH SCH CRAMB R HUTTON P
Citation: Jm. Thompson et al., CLINICAL-EVALUATION OF SODIUM-ION SELECTIVE FIELD-EFFECT TRANSISTORS FOR WHOLE-BLOOD ASSAY, Annals of clinical biochemistry, 31, 1994, pp. 12-17
METABOLIC EFFECTS OF CYCLOSPORINE-A AND FK-506 IN LIVER-TRANSPLANT RECIPIENTS
Authors: KRENTZ AJ DOUSSET B MAYER D MCMASTER P BUCKELS J CRAMB R SMITH JM NATTRASS M
Citation: Aj. Krentz et al., METABOLIC EFFECTS OF CYCLOSPORINE-A AND FK-506 IN LIVER-TRANSPLANT RECIPIENTS, Diabetes, 42(12), 1993, pp. 1753-1759
EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL LITER (200 TO 300 MG DL) PLUS 2 ADDITIONAL ATHEROSCLEROTIC RISK-FACTORS
Authors: BEHOUNEK BD MARKOWITZ JS BERGMAN M MCGOVERN ME KASSLERTAUB KB VANHANEN H ELORANTA M JUVONEN J KANTOLA I KEKKI S KIVELA H KNUTAR F NISSEN M SALMI J SALONEN R TARPILA S TUNTURIHIHNALA H AMANN FW BERENDES G BONNER G DUBACH UC EGGSTEIN M FRANKENBERG HV FROER KL HOHL H HOPPE F KUMMER H MARZ W MOCCETTI T NOSEDA G REUTTER FW SCHWENKE R VOSSCHULTE G WAMBACH G WEIDMANN P BONNIER JJRM DEWEERD P HUIGE MC JANSEN LJ TERIJDT AJ TEVELDE K OLSSON AG LARSSON H ASPLUND J DAHLQVIST A LONNQVIST F FRITHZ G HOGLUND C KJELLSTROM T KUYLENSTIERNA J MOLLER B OSTERGREN J CRAMB R DAVIES J",IVERSON,"JOHNSTON GD MUNRO A PEACOCK I RITCHIE LD RITTER J RYLANCE PB SEVER PS SIMMONS RL
Citation: Bd. Behounek et al., EFFECTS OF PRAVASTATIN IN PATIENTS WITH SERUM TOTAL CHOLESTEROL LEVELS FROM 5.2 TO 7.8 MMOL LITER (200 TO 300 MG DL) PLUS 2 ADDITIONAL ATHEROSCLEROTIC RISK-FACTORS, The American journal of cardiology, 72(14), 1993, pp. 1031-1037
COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF SIMVASTATIN AND PRAVASTATIN FOR HYPERCHOLESTEROLEMIA
Authors: DAUBRESSE JC DEBACKER G DUCOBU J HARVENGT C DEGENNES JL DOUSTEBLAZY P FARNIER M ANDERS G DAMMANN HG NEUMANN E SCHWARZE B SEIFART C KASTELEIN J STALENHOEF A KEIDAR S CAPURSO A DECESARIS R DESCOVICH G FELLIN R FERUGLIO F MALINI P TRIMARCO B SCOTT R MARAIS A KELLER U MOCCETTI T BLOOMFIELD P CRAMB R HUGHES E SEED M WRAY R STEIN E FRUCHART J SWEANY A SHAPIRO D TATE A
Citation: Jc. Daubresse et al., COMPARISON OF THE EFFICACY, SAFETY AND TOLERABILITY OF SIMVASTATIN AND PRAVASTATIN FOR HYPERCHOLESTEROLEMIA, The American journal of cardiology, 71(16), 1993, pp. 1408-1414
Risultati: 1-17 |